ArticleWorld journal of diabetes2025
Serum alpha-1-microglobulin as a predictor of multiple complications in type 2 diabetes mellitus patients.
Article in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Commentary on α-1-microglobulin as a predictor of diabetic complications.World journal of diabetes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoor glycaemic control in patients with type 2 diabetes mellitus (T2DM) is often accompanied by multiple complications, including diabetic nephropathy (DN), diabetic retinopathy (DR), diabetic peripheral neuropathy (DPN), and cardiac structural abnormality left ventricular hypertrophy (LVH). Early identification of high-risk populations for these complications and the implementation of intervention measures are crucial for improving patient outcomes. Serum alpha-1-microglobulin (α1-MG), a multifunctional protein synthesized by the liver and lymphocytes, has been considered a potential biomarker of diabetes-related diseases in recent years.
aimTo investigate the associations of serum α1-MG with DN, DR, DPN, and LVH in T2DM patients and its predictive value.
methodsThis retrospective study included 5045 T2DM patients. The study participants were stratified into quartiles according to their serum α1-MG levels. Multivariate logistic regression, restricted cubic spline, and explainable machine learning models were employed for risk assessment and feature importance evaluation.
resultsIncreased α1-MG levels were observed in patients with DN, DR, DPN, and LVH (all
conclusionElevated serum α1-MG levels were independently associated with increased risks of DN, DR, DPN, and LVH in T2DM patients, suggesting its potential as a predictive biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.